Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Clinical trial NCT02117362 · COMPLETED
Trial details
- NCT number
- NCT02117362
- Sponsor
- Providence Health & Services
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-08
- Primary completion
- 2018-11-28
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.